
|Videos|July 25, 2018
Best Practices in Molecular Profiling in NSCLC
Advertisement
Episodes in this series

Transcript:
Advertisement
Related to this article

Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued
2
CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease
3
T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer
4
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma
5


















